NFL Biosciences SA

Paris Stock Exchange ALNFL.PA

NFL Biosciences SA EBIT Margin for the year ending December 31, 2023

NFL Biosciences SA EBIT Margin is NA for the year ending December 31, 2023. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.
Key data
Date EBIT Margin EPS (Basic) EPS (Diluted) Shares (Basic, Weighted)
Market news
SV Wall Street
Paris Stock Exchange: ALNFL.PA

NFL Biosciences SA

CEO Dr. Ignacio Faus M.B.A., Ph.D.
IPO Date July 5, 2021
Location France
Headquarters 199 Rue Helene Boucher
Employees 4
Sector Consumers Staples
Industries
Tobacco Biotechnology Pharmaceuticals
Description

NFL Biosciences SA, a biotechnology company, develops natural addiction withdrawal solutions for smokers. Its natural drug candidate in pipeline to cure tobacco addiction include NFL-101, a tobacco extract that is in Phase III clinical trial targeting smoking addiction; NFL-201, a cannabis and tobacco extract, which is in preclinical stage; and NFL-301, a botanical extract (traditional Chinese medicine) that is in preclinical stage. The company was incorporated in 2006 and is based in Castelnau-le-Lez, France.

Similar companies

ABNX.PA

ABIONYX Pharma SA

USD 1.27

1.92%

StockViz Staff

February 7, 2025

Any question? Send us an email